LLY
Eli Lilly and Company
LLY has the edge over PRGO overall, supported by stronger fundamentals and lower modeled downside.
PRGO
Perrigo Company plc
PRGO's outlook is improving, though it still trails on the overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
PRGO Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Under pressure | |
| Weak |
PRGO's revenue is currently stable, but its profitability, cash flow and balance sheet are under pressure.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
PRGO PE Valuation
PRGO has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over PRGO on the outlook, with more favorable revenue expectations.
PRGO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect PRGO's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over PRGO on earnings quality, reporting a profit while its opponent remains loss making.
PRGO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.53 | — |
| Q3 2026 | -$12.77 | -$12.39 |
| Q2 2026 | -$12.52 | -$11.94 |
| Q1 2026 | -$13.11 | -$11.80 |
| Q4 2025 | -$10.29 | -$9.04 |
| Q3 2025 | -$0.38 | +$0.78 |
| Q2 2025 | -$0.58 | +$0.33 |
| Q1 2025 | -$1.31 | -$1.25 |
| Q4 2024 | -$1.25 | -$1.16 |
PRGO lost $12.77 per share over the past year, a bigger loss than the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over PRGO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over PRGO on profitability, with a higher operating margin.
PRGO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $988.6M | -5.2% |
| Q2 2026 | $1B | -3.2% |
| Q1 2026 | $969.2M | -7.2% |
| Q4 2025 | $1.1B | -2.5% |
| Q3 2025 | $1B | -4.1% |
| Q2 2025 | $1.1B | -0.9% |
| Q1 2025 | $1B | -3.5% |
| Q4 2024 | $1.1B | -1.6% |
PRGO's revenue has slid since its 2020 peak: $989M last quarter, down 5.2% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 2.3% | -4.6 points |
| Q2 2026 | 2.3% | -2 points |
| Q1 2026 | -38% | -43 points |
| Q4 2025 | -116% | -126 points |
| Q3 2025 | 7% | -0.4 points |
| Q2 2025 | 4.3% | +6.8 points |
| Q1 2025 | 4.5% | +9.6 points |
| Q4 2024 | 10% | +11 points |
PRGO's operating margin was 2.3% last quarter, down 4.6 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over PRGO on cash flow, with more consistent year-over-year improvement.
PRGO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $78.7M | +164% |
| Q2 2026 | $68.3M | +20% |
| Q1 2026 | -$127.4M | -$37.4M |
| Q4 2025 | $148.6M | -46% |
| Q3 2025 | $29.8M | +97% |
| Q2 2025 | $56.7M | +$75.6M |
| Q1 2025 | -$90M | -$63.5M |
| Q4 2024 | $274.9M | +51% |
PRGO still generates free cash flow, though less than at its 2021 peak: $168M over the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over PRGO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
PRGO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -200K shares |
| 1 year | +0.4% | +500K shares |
| 3 years | +1.8% | +2.5M shares |
| 5 years | +4.2% | +5.6M shares |
| Available history | +1.8% | +2.4M shares |
PRGO has 139M diluted shares, about the same as a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
PRGO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | 5.3x | High |
| Q2 2025 | 5.2x | High |
| Q1 2025 | 6.0x | High |
| Q4 2024 | 7.0x | High |
| Q3 2024 | 10.5x | High |
| Q2 2024 | 11.5x | High |
| Q1 2024 | 8.5x | High |
| Q4 2023 | 6.5x | High |
PRGO's net debt is about 5.3 years of its operating earnings (EBITDA), down from 10 years a year ago.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
PRGO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 61.8 | Neutral |
| Stochastic | 84.4 | Overbought |
PRGO's weekly RSI is 62 (neutral) and its Stochastic is 84 (overbought).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
PRGO PE vs Healthcare Sector
| Metric | PRGO | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
PRGO has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over PRGO on trend strength, trading above more of its moving averages.
PRGO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $15.6 | 3.5% above |
| 20 week MA | $13.7 | 18% above |
| 50 week MA | $12.8 | 26% above |
| 100 week MA | $18.5 | 13% below |
| 200 week MA | $24.9 | 35% below |
PRGO has bounced recently, but its long-term trend is still down: it's above its 8-, 20- and 50-week averages, but 35% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over PRGO on returns for 2026, with the stronger performance.
PRGO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $51.9 | $44.0 | -15% |
| 2021 | $44.0 | $39.5 | -10% |
| 2022 | $39.5 | $33.0 | -16% |
| 2023 | $33.0 | $32.2 | -2.5% |
| 2024 | $32.2 | $25.6 | -20% |
| 2025 | $25.6 | $13.8 | -46% |
| 2026 YTD | $13.8 | $16.2 | +17% |
PRGO has finished every year since 2020 lower, and it's up 17% so far in 2026.